{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-044496","form_type":"8-K","ticker":"MRKR","cik":"0001094038","company_name":"Marker Therapeutics, Inc.","filed_at":"2024-04-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.257244+00:00","generated_at":"2026-06-04T01:15:20.005966+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Marker Therapeutics: MT-601 shows durable CR in lymphoma patient 9 months post-CAR T failure; 3/3 objective responses","bullets":["First APOLLO participant with DLBCL who relapsed after CAR T remains in complete response 9 months after MT-601 treatment.","Second participant with transformed follicular NHL achieved CR at 8 weeks and remains in CR at 3 months.","Third participant with DLBCL (CAR T-ineligible) achieved partial response at 8 weeks with lesion shrinkage.","All three patients tolerated treatment well; no cytokine release syndrome or neurotoxicity reported.","Data presented at 11th Global Summit on Hematologic Malignancies on April 6, 2024 by City of Hope PI Dr. Shouse."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-044496","json":"https://secwatch.observer/filing/0001104659-24-044496.json","markdown":"https://secwatch.observer/filing/0001104659-24-044496.md","text":"https://secwatch.observer/filing/0001104659-24-044496.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1094038/000110465924044496/0001104659-24-044496-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1094038/000110465924044496/tm2411143d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T01:15:20.005966+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}